ibrutinib,venetoclax,rituximab
roche,janssen,abbvie,biogen
['ibru', 'n+i', 'congrat', 'cll']
update results of the british phase iii flair trial ven+ibru vs. ibru in 1l fit pts, more efficacy of the combination therapy. interesting concept of mrd - driven length of therapy. congrats to peter hillmen and all investigators. #cll 
Hematologist at https://t.co/5Cv9rH6CW0; CLL expert. Professor at https://t.co/iQLiqw0Vhp. Evidence-based medicine. Trumpet / chess / golf player. Tweets are solely my personal views.